Article info
Original research
Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis
- Correspondence to Dr Zhengyu Li, West China Second University Hospital, Sichuan University, No. 20 Section 3, Renmin South Road, Chengdu, Sichuan 610041, People’s Republic of China; zhengyuli{at}scu.edu.cn
Citation
Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis
Publication history
- Received March 11, 2020
- Revision received July 16, 2020
- Accepted July 17, 2020
- First published August 19, 2020.
Online issue publication
January 08, 2022
Article Versions
- Previous version (6 October 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.